IRCT20230110057096N1RecruitingPhase 3
Evaluation of efficacy of Nicorandil on incidence of contrast-induced nephropathy in patients with GFR < 60% and undergoing coronary angiography and percutaneous coronary intervention- A randomized clinical trial
Rasht University of Medical Sciences0 sites264 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Enrollment
- 264
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- no limit to no limit (—)
- Sex
- All
Inclusion Criteria
- •Patients with GFR<60 ml/min that do not undergo dialysis
- •Patients who are a candidate for non-emergent CAG or non-primary PCI and have 24-hour time for treatment with Nicorandil
Exclusion Criteria
- •Consuming Metformin, ACEI, ARB, Nicorandil, Nitrocontin, Sildenafil and other phosphodiesterase 5 inhibitors in the last 24 hours
- •having urinary tract infection(UTI)
Investigators
Similar Trials
Recruiting
Phase 3
Evaluation of the oral Nicorandil effect on reducing the contrast-inducedcardiac catheterization.IRCT20210620051631N1Mashhad University of Medical Sciences344
Completed
Phase 2
Efficacy of nicorandil in acute coronary syndromeAcute coronary syndrome.Ischaemic heart disease120_125IRCT201202189067N1Vice chancellor for research, Kermanshah University of Medical Siences and Health Services252
Recruiting
Phase 2
The effect of nicorandil on arrhythmiaIRCT20181104041555N1Zahedan University of Medical Sciences100
Recruiting
Phase 2
Effect of the drug Nicorandil in Peripheral Vascular DiseaseCTRI/2022/01/039444All India Institute of Medical Sciences Rishikesh
Completed
Phase 4
Clinical Efficacy and SAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary InterventionST Elevation Myocardial InfarctionPercutaneous Coronary InterventionNCT04665648Fudan University1,500